Press Room

More than 100 organizations representing millions of patients with serious health conditions and health care professionals sent a letter to Congress expressing their strong support for the Clinical Trial Modernization Act. Introduced in the House of Representatives in May 2025 by Reps. Raul Ruiz (D-CA) and August Pfluger (R-FL), the bipartisan legislation would help remove cost and geographic barriers to patient participation in clinical trials.

 A new ACS CAN study released in the Journal of the American Medical Association (JAMA) finds many patients aren’t made aware of the importance of pharmacogenomic (PGx) testing. A form of biomarker testing, PGx testing examines how variations in a patient’s inherited genes may impact how they respond to different drugs and can improve the effectiveness of treatment and reduce the risk of adverse drug reactions.

Today, the U.S. Senate Committee on Appropriations considered and approved its draft FY26 appropriations bill that includes increases for the National Institutes of Health (NIH) and increases for federal cancer research funding at the National Cancer Institute (NCI).

Today, the U.S. Senate voted to confirm Susan Monarez, PhD, as the next Director of the Centers for Disease Control and Prevention (CDC).

Un nuevo informe (en inglés) de la Oficina de Presupuesto del Congreso (CBO, por sus siglas en inglés), un organismo no partidista, concluye que los recortes propuestos a los Institutos Nacionales de la Salud (NIH) podrían reducir la cantidad de nuevos medicamentos que lleguen al mercado en las próximas tres décadas.

Following U.S. House passage of the budget bill containing the most devastating cuts to Medicaid in history and changes to the ACA Marketplace that will make it more expensive and difficult to obtain and keep health insurance, ACS CAN expresses deep disappointment and urges Congress to extend the enhanced ACA tax credits.

Today, the U.S. Supreme Court issued its ruling in the case of Kennedy v. Braidwood Management.

A bill introduced earlier this year in the House and Senate now has the bipartisan support of the majority of the members in each chamber.

WASHINGTON, D.C. –  Today, the president released his final proposed budget for Fiscal Year 2026 which contains $4.531 billion for the National Cancer Institute (NCI).

Hoy se presentó en el Senado de los Estados Unidos una legislación bipartidista para ampliar el acceso a las pruebas de detección del cáncer de mama y cuello uterino. La Ley de Pruebas de Detección para que las Comunidades Reciban los Servicios Necesarios de Manera Temprana y Equitativa para el Cáncer (conocida por sus siglas en inglés, SCREENS for Cancer Act) reautorizaría el Programa Nacional de Detección Temprana de Cáncer de Mama y Cuello Uterino (NBCCEDP, por sus siglas en inglés) para los años fiscales comprendidos entre 2026 y 2030.